Orphan Drugs for Rare Diseases Summit
22-23

March 2018

Germany

Berlin

Novotel Hotel Berlin Am Tiergarten

Str. des 17. Juni 31 106-108, 10623

About

We are pleased to invite you to the 2nd Precision Medicine Summit with focus on “Orphan Drugs for Rare Diseases“, scheduled for March 22-23, 2018 in Berlin, Germany. This premier B2B event provides the appropriate platform to engage and discuss ideas with your fellow peers while facilitating a professional atmosphere and environment for good company representation and development. The summit will shed light on current challenges, best practices and the inside view of the future of Orphan Drugs for Rare Diseases. We will discuss key findings,...

We are pleased to invite you to the 2nd Precision Medicine Summit with focus on “Orphan Drugs for Rare Diseases“, scheduled for March 22-23, 2018 in Berlin, Germany. This premier B2B event provides the appropriate platform to engage and discuss ideas with your fellow peers while facilitating a professional atmosphere and environment for good company representation and development. The summit will shed light on current challenges, best practices and the inside view of the future of Orphan Drugs for Rare Diseases. We will discuss key findings, including critical insights, as well as recommendations for driving efficient strategies in Orphan Drugs for Rare Diseases landscape. We look forward to welcoming you in Berlin upcoming March.

more info
Who Should Attend

Chief Executives, Directors, Vice Presidents, Heads, Leaders, and Managers specialising in:

  • Drug Discovery & Development
  • Translational Medicine
  • Innovative Medicine
  • Regenerative Medicine
  • Molecular Diagnostics
  • Cell / Gene Therapy
  • Rare & ultra-rare Diseases
  • Metabolic & Gastrointestinal (GI) disorders
  • Cardiovascular, pulmonological disorders
  • Neurology, mental health, neuromuscular and musculoskeletal disorder
  • Haematology
  • Non-Hodgkin Lymphoma
  • Cystic Fibrosis
  • Pancreatic Cancer
  • Multiple Myeloma
  • Graft vs Host Disease
  • Clinical Research / Trials / Development
  • Pricing & Reimbursement
  • Patient Advocacy
  • Regulatory & Medical Affairs
  • Health Economics/Outcomes Research (HEOR)
  • Bioinformatics
  • Digital Health
  • Personalized Medicine
  • Experimental Medicine
  • Stratified Medicine
  • Cell / Molecular Biology
  • Diagnostic Development
  • Targeted Therapy
  • Genetic Diseases
  • Endocrinology
  • Cancer / Oncology
  • Dermatology, ophthalmology, urology and nephrology Immunology
  • Immunology
  • Acute Myeloid Leukaemia
  • Glioma
  • Ovarian Cancer
  • Duchenne Muscular Dystrophy
  • Renal Cell Carcinoma
  • Market Access
  • Alliance Management
  • n-Licensing/Out-Licensing
  • Commercial Development
  • Orphan Foundations/Associations
  • Big Data
Key Practical Learning Points of the Summit

Cutting-edge science and tech to enhance rare diseases research, diagnosis and therapeutics
Novel drug modalities, assays & models, therapeutic strategies
Employee wellbeing & health in relation to office design
Emerging approaches for effective, fast, affordable and successful orphan drugs development
Insights into regulatory, pricing, reimbursement, commercialization, market access for rare disorders drugs
Speakers
Dr. Rajeev Sivasankaran, US

Head - Rare Diseases Neuroscience Division

Novartis Inst. for BioMedical Research

Nigel Nicholls, UK

Director & Country Manager UK/Ireland

BioMarin Europe Ltd

Dr. Pablo Sardi, US

Neuroscience Therapeutic Area

Sanofi

Dr. Immo Zadezensky, US

Head Global Regulatory & Scientific Policy (GRASP)

EMD Serono Research & Dev. Inst., A business of Merck KGaA

Martine Zimmermann, CH

Sr. Vice President / Head of Global Regulatory Affairs

Alexion Pharma GMBH

Dr. Peter Joyce, UK

CEO & Former Senior Research Scientist at Vertex Pharmaceuticals

Grey Wolf Therapeutics

Leung Ming Yu, NO

Scientific officer, HTA and Reimbursement

Norwegian Medicines Agency

Dr. Mania Ackermann, DE

Project Leader / REBIRTH unit „Translational Hematology of Congenital Diseases”

MHH / Institute of Experimental Hematology

David Dasberg, NL

Managing Director

Facio Therapies BV

Dr. Lutz Müller, CH

Project Leader Pharmaceutical Sciences

F. Hoffmann-La Roche Innovation Center

Dr. Maria Chiara Magnone, SE

Sr Director, Head of Translational Sciences CVMD iMed

AstraZeneca

Sarah Rickwood, UK

Vice President European Thought Leadership

IQVIA (formerly QuintilesIMS)

Annu Suchdev, SE

Head of Quality R&D & HCC, Global Quality and Compliance

Swedish Orphan Biovitrum AB

Micah Rose, UK

Technical Adviser, Health Economic Modelling, Scientific Advice

NICE

Dr. Marc Martinell, ES

CEO

Minoryx Therapeutics

Narayanan Gopalan, UK

VP, Disruptive Biologics

Voisin Consulting Life Sciences (VCLS)

Carole Jones, UK

Director, Market Access

Voisin Consulting Life Sciences (VCLS)

Nagore Fernandez, UK

Head of Patient Services for EUCAN

Ashfield

Matt Brierley, UK

VP Medical and Scientific Services

Ashfield

Annual

Events

Sponsors and Partners

Sponsor

Sponsor

Media partner

Media partner

Media partner

Media partner

Media partner

Media partner

Media partner

Media partner

Media partner

Media partner

Media partner